阿斯利康攜四項重要研究首發數據亮相歐洲腫瘤內科學會（ESMO）年會，進一步彰顯重新定義癌癥治療的雄心

2025-10-14 21:00

DESTINY-Breast11與DESTINY-Breast05兩項研究入選主席研討會（Presidential Symposium），凸顯德曲妥珠單抗在治療HER2陽性早期乳腺癌中的潛在價值

TROPION-Breast02研究數據將展示德達博妥單抗在轉移性三陰性乳腺癌這一最具侵襲性的乳腺癌分型中的治療潛力

POTOMAC研究的無病生存期數據與MATTERHORN研究的生存期數據將展示度伐利尤單抗在早期膀胱癌與胃癌治療中的獲益

上海2025年10月14日 /美通社/ -- 阿斯利康將于2025年10月17日至21日召開的歐洲腫瘤內科學會（ESMO）年會上，憑借?業領先的多樣化產品與管線布局的全新研究數據，進一步彰顯其重新定義癌癥治療格局的雄心壯志。

本次大會上，阿斯利康將公布逾95項摘要，涵蓋9款已獲得批準藥物及9款潛在新藥，包括2項入選重要主席研討會（Presidential Symposium）的摘要以及26項口頭報告。

其中主要亮點包括：

DESTINY-Breast11：評估德曲妥珠單抗序貫THP方案（紫杉醇、曲妥珠單抗及帕妥珠單抗）用于高風險HER2陽性早期乳腺癌新輔助治療的III期臨床研究（主席研討會1，摘要#291O）。
DESTINY-Breast05：評估德曲妥珠單抗用于HER2陽性早期乳腺癌（新輔助治療后存在殘留浸潤病灶并具有高復發風險）的III期臨床研究（主席研討會1，摘要#LBA1）。
TROPION-Breast02：評估德達博妥單抗用于一線治療無法接受免疫治療的局部復發性不可手術或轉移性三陰性乳腺癌（TNBC）患者的III期臨床研究（優選論文摘要#LBA21）。
POTOMAC：評估度伐利尤單抗聯合卡介苗（BCG）誘導與維持治療，用于高危非肌層浸潤性膀胱癌（NMIBC）患者的III期臨床研究（優選論文摘要#LBA108）。
MATTERHORN：公布III期臨床研究的最終總生存期（OS）結果，評估度伐利尤單抗聯合FLOT化療作為可切除的早期和局部晚期的胃和胃?管結合部腺癌（GEJ）患者圍手術期治療中的臨床獲益（優選論文摘要#LBA81）。

阿斯利康全球執行副總裁、全球腫瘤研發負責人高書璨（Susan Galbraith）表示："我們正加速推進多元創新療法管線，以變革乳腺癌患者的治療格局。在本屆ESMO大會上，我們將公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的數據和重要進展。同時，我們也將展示新一代潛在抗腫瘤新藥的數據，包括saruparib聯合新型激素療法用于前列腺癌領域，靶向葉酸受體的抗體偶聯藥物torvu-sam用于卵巢癌領域，以及rilvegostomig用于在非小細胞肺癌領域。"

阿斯利康全球執行副總裁，腫瘤業務負責人Dave Fredrickson表示："我們業界領先的腫瘤產品組合在本次ESMO持續展現強勁勢頭，首次公布了四項關鍵研究的數據。其中，不僅有德曲妥珠單抗和德達博妥單抗在乳腺癌領域的重大進展，度伐利尤單抗的POTOMAC試驗結果也證明了免疫療法為早期膀胱癌治療帶來的益處，進而闡釋我們的策略——將前沿治療引入癌癥早期這一患者最能夠獲益的階段。"

其他亮點包括：

FONTANA：評估靶向葉酸受體α（FRα）的抗體藥物偶聯物AZD5335用于鉑耐藥復發性卵巢癌患者的I/IIa期首次人體臨床試驗（簡短口頭報告摘要#1065MO）。
PETRANHA：評估saruparib聯合雄激素受體通路抑制劑用于治療轉移性前列腺癌患者的I/II期臨床研究（簡短口頭報告摘要#2384MO）。
ARTEMIDE-01：評估rilvegostomig用于檢查點抑制劑初治的轉移性非小細胞肺癌（NSCLC）患者的I/II期臨床研究（簡短口頭報告摘要#1853MO）。
FLAURA2：在奧希替尼合化療治療晚期EGFR突變NSCLC患者的FLAURA2 III期臨床研究中存在不良預后因素患者的探索性OS分析（優選論文摘要#LBA77）。
CAPItello-281：卡匹色替聯合阿比特龍和雄激素剝奪療法（ADT）用于PTEN缺陷的新發轉移性激素敏感性前列腺癌（mHSPC）的III期臨床研究（優選論文摘要#2383O）。
TROPION-PanTumor03：評估德達博妥單抗聯合rilvegostomig治療局晚期或轉移性尿路上皮癌（a/mUC）患者的療效： II期TROPION-PanTumor03研究結果結果（簡短口頭報告摘要 #3072MO）
BEGONIA：德達博妥單抗聯合度伐利尤單抗用于既往未經治療的不可切除、局部晚期或轉移性三陰性乳腺癌（TNBC）患者的BEGONIA Ib/II期試驗最終結果（口頭報告摘要#555MO）。

阿斯利康與第?三共聯合開發和商業化德曲妥珠單抗與德達博妥單抗；與默沙東（默沙東是美國新澤西州羅威市默克公司的公司商號）聯合開發和商業化奧拉帕利；與和黃醫藥合作開發和商業化賽沃替尼。Rilvegostomig是一種靶向PD-1和TIGIT的雙特異性抗體，其中TIGIT部分源自Compugen公司臨床階段的抗TIGIT抗體COM902。

阿斯利康在2025年ESMO年會期間的重要演講^[1]

主要作者	摘要標題	報告詳情(CEST)
抗體偶聯藥物
Harbeck, N	DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)	Abstract #291O Presidential 1 18 October 2025 4:30 PM
Geyer, C	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05	Abstract #LBA1 Presidential 1 18 October 2025 4:52 PM
Dent, R.	First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial	Abstract #LBA21 Proffered Paper Session 19 October 2025 9:25 AM
Loibl, S	Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer: additional analysis of DESTINY-Breast09 in key subgroups of interest	Abstract #LBA18 Proffered Paper Session 19 October 2025 8:30 AM
Rha, SY	Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study	Abstract #3072MO Mini Oral Session 17 October 2025 4:10 PM
Oaknin, A	First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer	Abstract #1065MO Mini Oral Session 19 October 2025 10:53 AM
Schmid, P	Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase 1b/2 BEGONIA study	Abstract #555MO Mini Oral Session 20 October 2025 10:50 AM
Raghav, K	Trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase 2 trial	Abstract #737P Poster Session
Peng, Z	Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06)	Abstract #2105P Poster Session
Shen, L	Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in the DESTINY-Gastric06 (DG-06) trial	Abstract #2175P Poster Session
Pietrantonio, F	Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04)	Abstract #2099P Poster Session
Makker, V	Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY- PanTumor02 (DP-02) Part 1 final analysis	Abstract #957P Poster Session
Lee, J-Y	Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1	Abstract #145P Poster Session
免疫腫瘤學
Tabernero, J	MATTERHORN Phase III trial of Imfinzi (durvalumab) perioperative Imfinzi (durvalumab) plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers	Abstract #LBA81 Proffered Paper Session 17 October 2025 2:00 PM
De Santis, M	Durvalumab (D) in Combination with Bacillus Calmette- Guérin (BCG) for BCG-naïve, High-risk Non-muscle- invasive Bladder Cancer (NMIBC): Results from the Phase 3, Open-label, Randomised POTOMAC Trial	Abstract #LBA108 Proffered Paper Session 17 October 2025 2:10 PM
Larkin, J	First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL	Abstract #LBA93 Proffered Paper Session 18 October 2025 9:20 AM
Aghajanian, C	Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA- mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025	Abstract #LBA44 Mini Oral Session 19 October 2025 11:31 AM
Goss, G	CCTG BR.31: Adjuvant durvalumab (D) in resected non- small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses	Abstract #LBA68 Mini Oral Session 20 October 2025 3:20 PM
Heymach, J	Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN	Abstract #LBA70 Mini Oral Session 20 October 2025 3:50 PM
Wermke, M	Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study	Abstract #2757O Proffered Paper Session 18 October 2025 8:30 AM
Loibl, S	Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial	Abstract #292MO Mini Oral Session 19 October 2025 10:15 AM
Van der Heijden, M	Health-related quality of life (HRQoL) from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC)	Abstract #3069MO Mini Oral Session 17 October 2025 4:00 PM
Sangro, B	Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the Phase 3 HIMALAYA study	Abstract #1494P Poster Session
Westin, S	Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial	Abstract #1117P Poster Session
Leal, TA	Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC	Abstract #1794P Poster Session
Reck, M	Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study	Abstract #LBA65 Proffered Paper Session 18 October 2025 9:15 AM
Maruki, Y	CELEBRATE Study (JCOG2107E): A Multicenter, Open- label, Phase III Trial of Etoposide, Carboplatin, and Durvalumab in First-line Treatment of Unresectable or Recurrent Digestive NEC	Abstract #1734TiP Poster Session
Oudard, S	A phase IIIb, open-label, single-arm, global study of perioperative durvalumab (D) with neoadjuvant dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)	Abstract #3133eTiP ePoster Session
雙特異性抗體
Chul Cho, B	Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small-Cell Lung Cancer (mNSCLC): ARTEMIDE-01	Abstract #1853MO Mini Oral Session 20 October 2025 10:25 AM
Slomovitz, BM	A randomized Phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair- proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG- 3098/ENGOT-EN24	Abstract #1223TiP Poster Session
Naidoo, J	ARTEMIDE-Lung04: A Phase 3, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%	Abstract #2025TiP Poster Session
腫瘤驅動因子和耐藥性
Jänne, PA	FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poor prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment for EGFR-mutated (EGFRm) advanced NSCLC	Abstract #LBA77 Proffered Paper Session 17 October 2025 4:56 PM
Mayer, E	Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)	Abstract #486MO Mini Oral Session 20 October 2025 10:25 AM
Arriola, E	Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC	Abstract #1817MO Mini Oral Session 20 October 2025 2:55 PM
Park, YH	Visual symptom questionnaire results from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1m during first- line (1L) therapy for patients (pts) with HR+/HER2- advanced breast cancer (ABC)	Abstract #528P Poster Session
Chu, Q	SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi	Abstract #1955P Poster Session
Rotow, J	MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Interim analysis of a global real world (rw) study	Abstract #1967P Poster Session
Yu, Y	ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)	Abstract #1954P Poster Session
DNA損傷應答
Azad, AA	First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)	Abstract #2384MO Mini Oral Session 17 October 2025 2:35 PM
Fizazi, K	A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281	Abstract #2383O Proffered Paper Session 19 October 2025 11:19 AM
Rugo, HS	Capivasertib with fulvestrant as first- and second-line endocrine therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial	Abstract #526P Poster Session
Gao, Q	Final overall survival (OS) analysis of L-MOCA: olaparib maintenance monotherapy in patients (pts) with platinum- sensitive relapsed ovarian cancer (PSR OC)	Abstract #1090P Poster Session
AI驅動的臨床試驗
Gonuguntla, HK	Real-World Validation of AI-defined Lung Nodule Malignancy Score (qXR-LNMS) in Predicting Risk of Lung Cancer: Interim results from Phase 2	Abstract #2978P Poster Session

^[1]阿斯利康在2025年ESMO年會將公布逾90個摘要，涵蓋其產品和管線中的分子藥物

關于阿斯利康腫瘤領域的研究

阿斯利康正引領著腫瘤領域的?場革命，致力提供多元化的腫瘤治療方案，以科學探索腫瘤領域的復雜性，發現、研發并向患者提供改變生命的藥物。

阿斯利康專注于最具挑戰性的腫瘤疾病，通過持續不斷的創新，阿斯利康已經建立了行業領先的多元化的產品組合和管線，持續推動醫療實踐變?，改變患者體驗。

阿斯利康以期重新定義癌癥治療并在未來攻克癌癥。

關于阿斯利康

阿斯利康（LSE/STO/Nasdaq: AZN）是?家科學至上的全球生物制藥企業，專注于研發、生產及營銷處方類藥品，重點關注腫瘤、罕見病以及包括心血管腎臟及代謝、呼吸及免疫在內的生物制藥等領域。阿斯利康全球總部位于英國劍橋，業務遍布超過125個國家，創新藥物惠及全球數百萬患者。更多信息，請訪問www.astrazeneca.com。

關于阿斯利康中國

阿斯利康自1993年進入中國以來，專注中國患者需求最迫切的治療領域，包括腫瘤、心血管、腎臟、代謝、呼吸、消化、罕見病、疫苗抗體及自體免疫等，已將40多款創新藥物帶到中國。阿斯利康中國總部位于上海，并在上海和北京設立全球戰略研發中心，在北京、廣州、杭州、成都、青島設立區域總部，在無錫、泰州、青島建立全球生產供應基地，向全球70多個市場輸送優質創新藥品。

聲明：本文研究中涉及的多種藥品用法尚未在中國獲批適應癥，阿斯利康不推薦任何未被批準的藥品使用。

消息來源：阿斯利康